Replies to post #3511 on AVEO Pharmaceuticals, Inc. (AVEO)

[stockguard]

AVEO Pharma (AVEO) is reiterated as a Buy over at B. Riley FBR today. Its analyst notes the following for his enthusiasm for the shares here early in 2018.

Today, January 16, we announce AVEO Pharmaceuticals (Buy, $5 PT) as an Out-the-Gate 2018 pick, due to our conviction in the success of lead asset Fotivda in the de-risked Phase III TIVO-3 trial in kidney cancer, with data expected in 2Q18. We see additional upside potential from the use of Fotivda with PD-1 inhibitor Opdivo in the Phase II TiNivo trial, with interim data expected at the ASCO GU conference on February 8–10, 2018. We thus reiterate our Buy rating on AVEO and our $5.00 price target.”

https://seekingalpha.com/article/4137707-biotech-daily-digest-january-16th